相关实验视频

Updated: Jul 18, 2025

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

开发和免疫保护的细菌状颗粒疫苗,以防感染性支气管炎在

Pengju Zhang¹, Tiantian Yang², Yixue Sun³

¹Institute of Animal Biotechnology, Jilin Academy of Agricultural Sciences, Changchun 130033, China.

|August 26, 2023

概括

一个新的候选疫苗,BLP-S1,显示传染性支气管炎病毒 (IBV) S1亚单元,显示了希望. 它有效诱导免疫反应,并保护90%的免受IBV感染.

科学领域:

兽医病毒学兽医病毒学
疫苗开发疫苗开发
禽类的健康禽类的健康

背景情况:

传染性支气管炎 (IB) 对全球家禽产业构成重大威胁.
目前的商业疫苗还没有完全控制传染性支气管炎病毒 (IBV) 疫情.
需要新的疫苗策略来有效控制IB.

研究的目的:

构建和评估BLP-S1,一种显示IBV S1亚单元的细菌样粒子,作为潜在的疫苗候选者.
评估BLP-S1对IBV感染的免疫性和免疫保护功效.

主要方法:

使用GEM-PA表面显示系统建造BLP-S1.
评估免疫反应,包括特定的IgG和sIgA,在免疫与BLP-S1.
在接种疫苗的中对IBV挑战的保护率的评估.

主要成果:

BLP-S1成功地显示了IBV S1子单位.
BLP-S1诱导了显著的特定IgG和sIgA免疫反应.
BLP-S1在中提供了90%的保护率,防止IBV感染.

结论:

BLP-S1表现出良好的免疫性和免疫保护对IBV.
BLP-S1具有开发新型传染性支气管炎疫苗的潜力.

关键词:

S1子单位 S1子单位类似细菌的颗粒.免疫保护性免疫保护性感染性支气管炎病毒感染性支气管炎病毒

更多相关视频

Expression and Purification of Virus-like Particles for Vaccination

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

相关概念视频

Vaccinations

Vaccinations

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.